May 2, 2023 – ARLINGTON, VA – The Bio-Process Systems Alliance (BPSA), the international association of the single-use bio-processing industry, announced the election of a Treasurer to its Executive Board and one Director-At-Large to its Board of Directors. Mr. Ravi Narayanan, Global Product & Market Management, Nordson Medical (Ft. Collins, CO) has been elected as BPSA Treasurer, succeeding Mr. Eric Isberg, who vacated the role last year. In addition, Mr. Scott Patterson, Vice President, PharmBio Technical Support, ILC Dover (Frederica DE) has been elected as Director-At-Large.

“The Alliance is pleased to welcome Ravi to the Executive Board as Treasurer and to welcome Scott to the Board as Director-At-Large,” said BPSA Chairman Mark Petrich of Krystal Biotech. “Ravi has been very active in BPSA and has served on the Board of Directors since 2022. Scott has been an active contributor and has been involved in BPSA activities for a number of years. I look forward to working with each of them to advance the use of single-use technologies in biopharmaceutical and vaccine production and to promote the mission and objectives of BPSA.”

Ravi Narayanan has over twenty-five years of leadership experience in product management and strategic marketing, new product development, and program management in the biopharmaceutical and medical industries. Ravi joined the BPSA Board in 2022 and has served in leadership positions in several other industry organizations affiliated with medical and biopharma devices, and disposables.

Scott Patterson has been active in a range of processing technologies for over 40 years with the past 25 years emphasizing pharmaceutical and biopharmaceutical processing. As a Vice President and Technical Leader with ILC Dover, Scott has focused on the use of single-use systems applied for high containment when handling potent compounds or solving large molecule upstream processing challenges. Scott has participated in multiple industry advocacy organizations including two BPSA committees.

The complete roster of BPSA Board Members can be found here: https://bpsalliance.org/about/board-of-directors/

About BPSA

The Bio-Process Systems Alliance (BPSA), an affiliated organization of the Society of Chemical Manufacturers & Affiliates (SOCMA), was formed in 2005 as an industry-led association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. Learn more at www.bpsalliance.org

December 19, 2022 – ARLINGTON, VA. – The Bio-Process Systems Alliance (BPSA), the international association of the single-use bio-processing industry, is pleased to announce the election of the following BPSA Executive Board members and Directors-at-Large for 2023/2024. 

Mark Petrich, PhD, Vice President, Process Development and Validation, Krystal Biotech, Inc. has been elected BPSA Chair, 2023-2024; Joseph St. Laurent, Head of Industry Relations & Regulatory Expert, Solvias, Inc. has been elected First Vice Chair; Todd Kapp, Global Commercial Development Director-Life Sciences, Entegris, Inc., has been elected Second Vice Chair, and Hernan Parma of Renolit Healthcare and Danielle Arcuri of Qosina, Inc. have been elected to the Board as Directors-at-Large. 

“I want to congratulate Mark on being elected BPSA Chair” said BPSA outgoing Chair, Jeff Carter, PhD, of Cytiva, whose term as Chair is ending on December 31, 2022. “The BPSA Board represents the entire value chain of the single-use industry, inclusive of resin producers, component manufacturers, system integrators, global OEM suppliers, analytical laboratories and end-users, and we are pleased to have an end-user/pharmaceutical manufacturer in the role of BPSA Chair for the first time.”

“I also want to congratulate Joseph St. Laurent of Solvias, Inc. on being elected First Vice Chair, Todd Kapp of  Entegris, Inc., on being elected Second Vice Chair, and Hernan Parma of Renolit Healthcare and Danielle Arcuri of Qosina, Inc. on being elected to the Board,” Carter continued. “We thank each of our volunteer leaders for their desire to serve on the BPSA Board, and we look forward to working with them in continuing to advance the adoption and use of single-use manufacturing processes and systems in vaccine and biopharmaceutical production. We also want to thank Robert Sassa of W. L. Gore and Scott Herskovitz of Qosina, whose terms as Directors-at-Large are ending this year.” 

Mark has been active with BPSA for include over ten years, including Board and Executive Board service, first with Merck & Co., Inc., and now at Krystal Biotech, Inc. He has served as Chair of the BPSA End-User Committee, co-authored several BPSA white papers, and helped successfully launch the BPSA Sustainability Committee. 

“It’s an honor to be elected to serve as BPSA Chair for 2023-2024. I want to thank Jeff for his service to the board and his leadership as Chair,” said Petrich. “Under Jeff’s leadership, the Alliance continued to grow and to serve the needs of its members and the biopharmaceutical industry. Many of the changes and challenges presented by the COVID-19 pandemic were addressed by single-use technologies and the efforts of BPSA member companies. As demand for single-use bioprocessing systems increased, Jeff’s leadership was key to putting BPSA in a position to help our members and the patients we all serve. I look forward to working with all the BPSA members and our volunteer leaders, as well as our partners and allied organizations, to continue to advance BPSA and the single-use bioprocessing industry.”

The roster of 2023/2024 Board Members is as follows:

BPSA Executive Board Officers: 

  • Chair: Mark Petrich, Krystal Biotech, Inc.
  • First Vice-Chair: Joseph St. Laurent, Solvias, Inc. 
  • Second Vice Chair: Todd Kapp, Entegris, Inc.
  • Treasurer:  VACANT
  • Secretary: Todd Andrews, CPC
  • Scientific Advisory Board Chair, Technical Committee Chair: Kirsten Strahlendorf, Sanofi Pasteur

At-Large Directors (newly elected/re-elected) through 2024:

  • Danielle Arcuri, Qosina Corporation
  • Ralph Daumke, PendoTECH
  • Patrick Evrard, Pall Corporation
  • Charlotte Masy, GSK Vaccines
  • Ravi Narayanan, Nordson Medical
  • Hernan Parma, Renolit Healthcare
  • Mark Sitcoske, High Purity New England
  • Elisabeth Vachette, Sartorius Stedim Biotech

At-Large Directors continuing through 2023:

  • Monica Cardona, MilliporeSigma
  • Brian Chung, Solvay, Inc.
  • Dan Rosen, Thermo Fisher Scientific

About BPSA

The Bio-Process Systems Alliance (BPSA), an affiliated organization of the Society of Chemical Manufacturers & Affiliates (SOCMA), was formed in 2005 as an industry-led association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. BPSA facilitates education, sharing of best practices, development of consensus guides and business-to-business networking opportunities among its member company employees. For more information, visit www.bpsalliance.org, or contact Executive Director Chris Clark at cclark@socma.org.

ARLINGTON, Va., Oct. 4, 2022 /PRNewswire/ — The Bio-Process Systems Alliance (BPSA), the international association of the single-use bio-processing industry, announced the election of a Secretary to its Executive Board and three at-large members to its Board of Directors for 2022-2023.

Todd Andrews, Director of Application & Business Development, Colder Products Company (CPC) will serve as Secretary, and new at-large members are:

  • Monica Cardona, Global Senior Program Manager, Single Use & Integrated Systems, MilliporeSigma
  • Brian Chung, Senior Key Account Manager – Specialty Polymers, Solvay
  • Dan Rosen, Vice President & General Manager – Single Use Technologies Flexible Solutions, Thermo Fisher Scientific

“The Alliance is pleased to have Todd Andrews join the Executive Board as Secretary,” said BPSA Chairman Jeff Carter of Cytiva. “He is very active in BPSA and has served on the Board of Directors for a number of years. I also welcome Monica Cardona, Dan Rosen and Brian Chung to the Board. I look forward to working with each of them to advance the use of single-use technologies in biopharmaceutical and vaccine production and advance the mission and objectives of BPSA.”

Todd has been involved in the single-use biopharmaceutical industry for more 15 years with a focus on single-use connection technology and has been an active BPSA member for almost 10 years. Todd has a bachelor’s degree in Plastics Engineering from University of Massachusetts, Lowell, and a master’s in business administration from the University of Saint Thomas.

Monica has been MilliporeSigma since 2019, and her previous roles include senior-level marketing and product management in the single-use and integrated systems sector. Monica served as Senior Marketing Manager-Single Use & Integrated Systems, and prior to her roles at MilliporeSigma, Monica was Global Product Manager Personal Protection Equipment with Cantel Medical Company and was Global Product Manager at Pall Life Sciences. Monica holds a bachelor’s degree in biology from Hofstra University and a master’s degree in biology from Adelphi University.

Prior to his role as Senior Account Manager at Solvay, Brian served as a Digital Sales Account Manager for Specialty Polymers and as Product Manager-Sulfation, Phosphation and Concentrates at Solvay. Brian holds a Bachelor of Science/M.S.E. in Chemical & Biomolecular Engineering from Johns Hopkins University.

Dan has been with Thermo Fisher Scientific for five years, and previously served as VP-GM for the company. Rosen has previous experience and expertise in investment banking and strategy consulting. Dan holds a bachelor’s degree from Brown University and a master’s in business administration from the Tuck School at Dartmouth College.

The complete roster of BPSA Board Members can be found here: https://bpsalliance.org/about/board-of-directors/

About BPSA

The Bio-Process Systems Alliance (BPSA), an affiliated organization of the Society of Chemical Manufacturers & Affiliates (SOCMA), was formed in 2005 as an industry-led association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. Learn more at www.bpsalliance.org

Arlington, VA – The Bio-Process Systems Alliance (BPSA) announced the publication of its latest guide, the 19-page Single-Use Technologies Enable Manufacturers to Meet Pivotal Challenges of Viral Vector Manufacturing.

Recent years have seen dramatic breakthroughs in cell and gene therapies. Cell and gene therapy (CGT) is a science that is ushering in a new era in medicine. One of the main focuses of this technique is the optimization and delivery of Viral Vector vehicles that are mostly nanostructures, or viruses.

This new BPSA guide discusses present and future challenges in gene therapy manufacturing and how single-use technologies (SUTs) can improve the manufacturing process, including upstream production and downstream purification; product and operator safety; processing in closed systems and how single-use technology enables cost-effective manufacturing. The white paper also sheds light on some of the future opportunities for SUTs in gene therapy production.

“SUT’s are essential to viral vector manufacturing success, and this guide provides insights that will enable biopharmaceutical manufacturers to make smart choices about where single use can improve outcomes and speed of therapies to market,” said Brendan Lucey, Global Director of Cross Business Unit Market Strategy, Entegris, and Chair of the BPSA Cell and Gene Therapy Committee.

Viral Vector manufacturing is still in an early stage of development, and this emerging segment in biopharmaceutical manufacturing is benefiting from the recent surge in production of vaccines and monoclonal antibodies in response to the Covid-19 pandemic. While challenges still exist in the scale-up of Viral Vector manufacturing components, SUTs have been almost fully integrated in the process at commercial scale, and the SUT supply base is actively responding to these needs.

“The Viral Vector white paper is the culmination of an 18-month process, and I want to thank the BPSA Cell and Gene Therapy Committee, and all of the authors, contributors and editors for their hard work on this guide,” said Chris Clark, BPSA Executive Director. “BPSA and the single-use supply chain continues to work collaboratively to ensure a robust, safe, and reliable manufacturing base for cell and gene therapy production.”

Contact BPSA Executive Director, Chris Clark, to learn more, or visit the BPSA website to download a copy.


About BPSA
The Bio-Process Systems Alliance (BPSA), an affiliate of SOCMA, was formed in 2005 as an industry-led international industry association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. www.bpsalliance.org.

June 14, 2022 – Arlington, VA.–The Bio-Process Systems Alliance (BPSA), an affiliate of the Society of Chemical Manufacturers & Affiliates (SOCMA), announced it has named Christopher Clark, CAE, as its new Executive Director, effective June 1. Clark succeeds Kevin Ott, who served as BPSA Executive Director from 2007-2022.

“I want to congratulate and thank Kevin Ott for his 15 years of leadership and dedication to BPSA as Executive Director. Kevin has been with BPSA since the Alliance’s formation, and the organization would not be where it is today without his strategic guidance,” said BPSA Board Chair Jeff Carter, PhD, Consumables Product Strategy Leader, Cytiva.

Clark has spent more than 16 years in senior roles with national trade associations. As Executive Director, Clark will assume all day-to-day responsibilities of BPSA and work closely with the board of directors, membership, and affiliate partner the Society of Chemical Manufacturers & Affiliates (SOCMA), to ensure continued growth of the organization.

“The leadership and accomplishments Chris brings in association management make him an ideal choice for BPSA’s new Executive Director,” said Carter. “He brings significant leadership experience advocating for members and developing association programs and I look forward to working with him as we begin
the next chapter of our organization.”

Clark joins BPSA most recently from the North American Millers’ Association, where he served as Vice President, Communications & Administration. Prior to that, he was Vice President of Operations at the American Bakers’ Association, and Vice President of Operations, Member Service & Education at the
Snack Food Association (SNAC International). Clark is a Certified Association Executive (CAE) and member of the American Society of Association Executives.

“I am honored to join BPSA as its new Executive Director,” said Clark. “Single-Use Technologies are transforming how bio-pharmaceutical companies produce and deliver vaccines and other vital products, and I look forward to working with the BPSA membership and staff to advance the single-use
biopharmaceutical manufacturing industry,” said Clark.

About BPSA
Formed in 2005, the Bio-Process Systems Alliance (BPSA) is an industry-led international industry association of nearly 70 member companies dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. BPSA’s mission is to facilitate, globally, the development and manufacturing of biopharmaceuticals through the implementation of robust, safe and sustainable Single-Use Technologies.
www.bpsalliance.org

Contact
Chris Clark cclark@socma.org 571-348-5109

ARLINGTON, Va., Nov. 2, 2021 /PRNewswire/ — The Bio-Process Systems Alliance (BPSA), the international industry association of the single-use bio-processing industry, is pleased to announce the election of Board of Directors members who will serve two-year terms in leadership roles through December 31, 2023.

“With this election cycle we’re pleased to welcome back three members of our leadership team for new terms, as well as two re-elected at-large Directors, and two new Directors,” said Kevin Ott, BPSA Executive Director.

“As a unified Board, they represent a highly diverse leadership team that continues to work on issues of importance to the entire value chain of the single-use bio-processing industry, including resin suppliers, component manufacturers, systems integrators, auxiliary service and equipment suppliers and users,” Ott said. “This diversity is the historic strength of BPSA, and that tradition continues with our 2022/2023 slate of Board members.”

Executive Board officers for 2022-2023 are:

  • BPSA Treasurer: Eric Isberg, Savillex
  • Corporate Secretary: Janmeet Anant, Millipore Sigma
  • Scientific Advisory Board Chair: Kirsten Strahlendorf, Sanofi Pasteur Board of Directors members for 2022-2023 are:
  • Mukta Acharya, Thermo Fisher Scientific
  • Anna Maria Bertasa, Solvay Specialty Polymers
  • Todd Kapp, Entegris, Inc.
  • David Radspinner, ILC Dover

Continuing roles on the Executive Board through 2022 are:

  • Chair: Jeff Carter, Cytiva
  • First Vice-Chair: Mark Petrich, Krystal Biotech
  • Second Vice-Chair: Joseph St. Laurent, Chemic Laboratories, Inc.

Board of Directors members continuing through 2022 are:

  • Todd Andrews, CPC
  • Ralph Daumke, FILTROX AG
  • Patrick Evrard, Pall Corporation
  • Scott Herskovitz, Qosina Corporation
  • Charlotte Masy, GSK Vaccines
  • Ravi Narayanan, Nordson Medical
  • Robert Sassa, W.L. Gore & Associates
  • Mark Sitcoske, High Purity New England
  • Elisabeth Vachette, Sartorius Stedim Biotech

Both the Board and Executive Board hold bi-monthly virtual meetings. BPSA currently has 68 corporate members and is the primary trade association for the single-use industry. Headquartered in Washington, DC, BPSA has represented the full value-chain of single-use interests since 2005.

About BPSA

The Bio-Process Systems Alliance (BPSA), an affiliated organization of the Society of Chemical Manufacturers & Affiliates (SOCMA), was formed in 2005 as an industry-led corporate member industry association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. BPSA facilitates education, sharing of best practices, development of consensus guides and business-to-business networking opportunities among its member company employees. For more information, visit www.bpsalliance.org, or contact Executive Director Kevin Ott at kott@socma.org.

CONTACT: Kevin Ott, Executive Director, BPSA, (571) 348-5104, kott@socma.org

Guide defines roles and responsibilities of suppliers and users of polymeric single-use systems

ARLINGTON, Va., Feb. 18, 2021 /PRNewswire/ — The Bio-Process Systems Alliance (BPSA), the international association of the single-use bio-processing industry, is pleased to announce the release of its 2021 technical guide: Transit Testing Guidance for Single-Use Components and Assemblies.

The safety and performance of single-use bioprocess polymeric equipment, employed to manufacture biologic therapies and vaccines, is based on sterility and integrity and other stringent validation controls.

Delivery of single-use (SU) products requires that equipment be handled both mechanically and manually throughout the entire supply chain, from the point of manufacture to the point of use. In this vein, understanding supply chain hazards related to human error, shock, vibration, heat, compression and atmosphere will help determine the need and approach for in-depth, risk-based transit testing.

As detailed in the guide, a risk assessment may be based on the process step, the type of distribution cycle, historical data, or the nature/scope of a packaging change or new design being implemented. The guide will assist the reader in determining the proper approach, or need for, transit safety testing either in a field or laboratory setting.

The full-color, illustrated guide includes a comprehensive set of terms and definitions, and appendices inclusive of ASTM, FDA, PDA, ISTA, EMA and ISO references, among others.

The 28-page illustrated guidance document represents an 18-month project, funded by BPSA, and produced by a wealth of subject-matter experts in the areas of transportation, packaging, quality assurance, vaccine and biologic production and physical product testing.

The writing team was led by Smithers. Additional authors are subject matter experts (SMEs) from Sartorius- Stedim Biotech, Entegris, Inc., Repligen Corporation, CPC, Pall Medistad BV, Sanofi Pasteur Ltd, and the Michigan State University School of Packaging. The guide is available for complimentary download at www.bpsalliance.org

About BPSA

The Bio-Process Systems Alliance (BPSA), an affiliate of SOCMA, was formed in 2005 as an industry-led international association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals, cell and gene therapies and vaccines. www.bpsalliance.org.

CONTACT: For more information, e-mail BPSA Executive Director Kevin Ott at kott@socma.org.

Single-use technology (SUT) has had a major impact on how precision biologic therapies are manufactured. So, what does the future hold for SUT in a world where single-use plastics are increasingly seen as an “eco-threat” instead of a means to manufacture life-saving therapies? Kevin Ott explains why sustainability is a complicated concept, but one that must be addressed by the single-use industry as we move into the next decade of SUT adoption and growth.

AS AN INDUSTRY group with a presence in both Europe and North America, the Bio-Process Systems Alliance (BPSA) welcomes this opportunity to reflect upon the unprecedented growth of SUT adoption over the past decade. More importantly, for the readers of European Pharmaceutical Review, we would also like to offer a cogent view of what may lie ahead. If “what is past is prologue” there is a robust future for SUTs, provided that innovation, risk management, continuous improvement investments, product enhancements and sustainable practices continue to be implemented.

The BPSA mission
Reflecting a little; since BPSA’s inception in 2005, we have viewed the accelerated be in double-digit CAG territory – and also ‘sustainable’ in the context of its merits adoption of SUTs as a global endeavor. This goal is, and always has been, evident in our mission statement, which remains: “Advancing Single-Use Worldwide”. Though our business presence is based in Washington, DC, a key element of our strategic intent is to be a global industry association, focusing on the key features and benefits of polymer-based bioprocessing.

Looking ahead: sustained SUT growth beyond 2020
Perspectives on what lies ahead can be garnered by addressing the duality of the question: “is single-use sustainable?” The issue of sustainability can be viewed in terms of maintaining its impressive growth and adoption numbers – now estimated to as a high-performance, environmentally friendly alternative or hybrid supplement to traditional steel systems.

The answer in both cases is yes; provided that the industry continues to be problem solvers of the first order – and this includes staying on top of end-user risk mitigation issues and addressing and promoting its environmental sustainability benefits.

Healthy business growth has not been granted to the SUT business because SUTs are new and better – the hard-earned industry growth of SUT is due to consistent and effective industry collaborations (along with international regulatory and standards bodies) that have addressed common problems, or hurdles, to the adoption of SUTs; including managing a paradigm shift from steel to polymers – a significant and unprecedented transition of process methodologies.

These collaborations have focused on risk reduction around critical matters, including system leak integrity, change control management, resin consistency, extractables data, particulates identification and control, workforce training and education and now sustainability in its many iterations.

Based on these problem-solving efforts, SUT adoption continues to evolve as a safe, efficient and affordable bioprocess platform. Furthermore, looking ahead, as current traditional manufacturing systems approach an age where significant equipment re-purchase must be carried out or a line must be upgraded, or a new facility built to improve efficiency or to increase output; transition to single-use manufacturing lines will increase due to the need to produce new drugs or therapies quickly, with the flexibility and speed-to-market benefits that SUT provides. The future is bullish and preparation for new markets and new challenges is key.

The emergence of cell and gene therapy (CGT) markets: new SUT opportunities
And prepare we must. Beside the anticipated continued growth in traditional single-use – ie, large-molecule bioprocessing – on the horizon, there are now new markets for SUTs, as exemplified by the emerging field of CGTs. Much has been written and discussed about CGT promises and challenges. Scalability, automation and cost-minimisation are key drivers prior to commercialisation of CGT (along with regulatory hurdles) and CGT cures will only happen inside of precision plastics systems, which are yet to be invented. These challenges are addressed in a BPSA whitepaper which fully addresses and dissects the technical challenges of scaled CGT manufacture.

To clarify, CGT, as with large-molecule bioprocess, shares patient safety as a firstorder concern, with little margin for error. Patient-specific therapies will re-double the scrutiny needed for particulate control, extractables, leak integrity, operator training, logistics, lead times and process control. Is the SUT supply base ready? Again, if past is prologue, the SUT supply base will again step up to these urgent challenges through collaborative innovation and co-operation, making curative therapies available to the acutely and chronically ill at accessible prices.

Future SUT challenges: the duality of sustainability and post-use disposal
Returning to the ‘S Word’ – sustainability: It’s here to stay. We’re all aware that SUTs are diverse systems inclusive of many types of polymers, silicones and thermo-plastics. There is no question, in a world awash with used plastic in landfills, rivers, oceans and storm systems, that the SUT industry must deal with matters of sustainable corporate practices and sensible disposal of post-use waste, ie, smart disposal.

As a caveat, in our growing market sector there is still no firm number of the pounds or kilos of used plastic that can be tied to SUT production and use. Overall, however, plastics are experiencing an unprecedented public relations drubbing. A quick visit to www.ibanplastic.com (and there are hundreds of similar sites) reveals that one million plastic bottles are bought every minute, 500 million straws are given out every day and an estimated four trillion plastic bags are used worldwide annually, with just 1 percent of them being recycled. None of these statistics are verifiable, but the pictures we have all seen tell the story: harmed wildlife, dirty rivers and Pacific Ocean plastic “gyres.” How much of that is SUT-related? We don’t know, but we hope it is minimal.

To further the challenge, sustainability in SUTs has two elements: the sustainable merits of SUT as employed in a process (ie, sustainable use) and the need for environmentally-sound, post-use disposal (smart disposal).

In terms of sustainable use, SUTs offer clear benefits. Extensive lifecycle analyses (LCA) of plastics versus steel systems have been carried out, which indicate that in many cases, SUTs can lead to a reduction in water depletion, climate change, ozone depletion and human toxicity, among others. When using SUTs there may be a reduction of water for injection, process water and steam, as well as fewer requirements for cleaning and sanitation in place. Consequently, there is a common belief that single-use processes are, in fact, sustainable compared to alternatives. Overall, LCA studies have revealed that single-use process technology is often less environmentally impactful than traditional metal processes, with some exceptions based on a combination of geography and process scale. It is indeed a complicated issue.

In terms of smart disposal, polymeric bioprocess systems are mixes of component polymers, which present a challenge to recyclers. End-of-life options (besides recycling) include landfill, incineration and pyrolysis, each of which offers benefits and problems. So, what are ‘end of life’ options for our waste plastics? Probably a combination of the above. The BPSA has formed a Sustainability Council, which meets bi-monthly to address these issues and expects to publish two guidance documents around sustainability in Q4 of 2019. Please stay tuned and visit our website for further information.

Final perspectives
It has been said that “single-use saves” – it saves time, money, resources and lives. For these compelling reasons, and others, it does appear that SUTs are poised for market growth well into the next decade – provided the industry remains focused on the mission to innovate, invest and collaborate, with an eye on sustainable practices.

About BPSA
The Bio-Process Systems Alliance (BPSA), an affiliate of SOCMA, was formed in 2005 as an industry-led international association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals, cell and gene therapies and vaccines. www.bpsalliance.org.

CONTACT: For more information, e-mail BPSA Executive Director Kevin Ott at kott@socma.org.